Global Postmenopausal Osteoporosis Drugs Market 2016-2020

閉経後骨粗鬆症治療薬の世界市場2016-2020

◆タイトル:Global Postmenopausal Osteoporosis Drugs Market 2016-2020
◆商品コード:IRTNTR9271
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2016年5月11日
◆ページ数:60
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥315,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、閉経後骨粗鬆症治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、閉経後骨粗鬆症治療薬の世界市場規模及び予測、治療クラス別分析、地域別分析/市場規模、購買基準、市場の成長要因、市場の課題、市場動向、競争状況などの情報をお届けいたします。

・エグゼクティブサマリー
・市場概観
・業界の構造分析
・疾患概要
・閉経後骨粗鬆症治療薬の世界市場:市場規模及び予測
・閉経後骨粗鬆症治療薬の世界市場:治療クラス別分析
・閉経後骨粗鬆症治療薬の世界市場:地域別分析
・閉経後骨粗鬆症治療薬の世界市場:アジア市場規模
・閉経後骨粗鬆症治療薬の世界市場:アメリカ市場規模
・閉経後骨粗鬆症治療薬の世界市場:ヨーロッパ市場規模
・閉経後骨粗鬆症治療薬の世界市場:成長要因
・閉経後骨粗鬆症治療薬の世界市場:課題
・購買基準
・市場動向
・競争状況
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

About the Postmenopausal Osteoporosis Drugs Market
Bones have the ability to grow and heal naturally, but changes in diet, exercise levels, and body chemistry lead to changes in the bone mineral density. This results in osteoporosis, which is characterized by low bone density and structural deterioration of bone tissues, leading to fragile bones. Rapid bone resorption or slow bone replacement can result in the development of the disease. Gender, age, body size (low body weight), ethnicity, and family history also play a role in developing osteoporosis. Other risk factors include medication, calcium and vitamin intake, alcohol intake, and smoking.

Women are at a greater risk of developing osteoporosis than men as estrogens play an important role in maintaining bone strength. Small amounts of bone are lost as part of normal aging process, but on reaching menopause, estrogen levels decline drastically, leading to a greater risk of developing osteoporosis.

Technavio’s analysts forecast the Global Postmenopausal Osteoporosis Drugs Market to grow at a CAGR of 4.02% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the Global Postmenopausal Osteoporosis Drugs Market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent postmenopausal osteoporosis.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Postmenopausal Osteoporosis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Eli Lilly
• Amgen
• Merck
• Novartis

[Other prominent vendors]
• Allergan
• Amgen Astellas Biopharm
• Deltanoid Pharmaceuticals
• Noven
• Novo Nordisk
• Osteologix
• Pfizer
• PhytoHealth
• Radius Health
• Tarsa Therapeutics
• UCB
• Uni-Bio Science Group
• Upsher-Smith Laboratories
• Watson Pharmaceuticals
• Zosano Pharma

[Market driver]
• Growing prevalence of postmenopausal osteoporosis
• For a full, detailed list, view our report

[Market challenge]
• Low diagnosis rate
• For a full, detailed list, view our report

[Market trend]
• Emergence of novel agents
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding postmenopausal osteoporosis
• Epidemiology and demography
• Risk factors
• Symptoms
• Diagnosis
• Treatment

PART 06: Key buying criteria

PART 07: Pipeline scenario
• TBRIA
• Romosozumab (AMG785)
• Odanacatib (MK-0822)
• Abaloparatide SC/Abaloparatide transdermal patch
• PHN-031 (PH3)
• NB S101
• Teriparatide ZP Patch (ZP-PTH)
• Blosozumab (LY2541546)

PART 08: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 09: Market segmentation by therapeutic class
• Antiresorptive medications
• Anabolic medications

PART 10: Market segmentation by line of therapy

PART 11: Geographical segmentation
• Global postmenopausal osteoporosis drugs market by geographical segmentation 2015-2020
• Postmenopausal osteoporosis drugs market in Americas
• Postmenopausal osteoporosis drugs market in EMEA
• Postmenopausal osteoporosis drugs market in APAC

PART 12: Market drivers
• Increase in older population
• Growing prevalence of postmenopausal osteoporosis
• Expected launch of promising pipeline molecules
• High unmet medical needs

PART 13: Impact of drivers

PART 14: Market challenges
• Multiple patent expiries
• Low diagnosis rate
• Nonadherence to treatment regimen
• Drug reimbursement issues

PART 15: Impact of drivers and challenges

PART 16: Market trends
• Awareness programs and initiatives
• Emergence of novel agents
• Emergence of combination therapies

PART 17: Vendor landscape
• Competitive scenario
• Market analysis 2015
• Eli Lilly
• Amgen
• Merck
• Novartis
• Other prominent vendors

PART 18: Appendix
• List of abbreviations

PART 19: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Prevalence of osteoporosis based on gender 2015
Exhibit 03: Interpretation of BMD results
Exhibit 04: Timeline for development of osteoporosis drugs
Exhibit 05: Key buying criteria for postmenopausal osteoporosis drugs
Exhibit 06: Pipeline portfolio: Postmenopausal osteoporosis
Exhibit 07: Global postmenopausal osteoporosis drugs market 2015-2020 ($ billions)
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of global postmenopausal osteoporosis drugs market by therapeutic class
Exhibit 10: Segmentation of global postmenopausal osteoporosis drugs market by therapeutic class on basis of revenue 2015
Exhibit 11: Segmentation of global postmenopausal osteoporosis drugs market by line of therapy
Exhibit 12: Segmentation of global postmenopausal osteoporosis drugs market by line of therapy on basis of revenue 2015
Exhibit 13: Segmentation of global postmenopausal osteoporosis drugs market based on geography 2015
Exhibit 14: Global postmenopausal osteoporosis drugs market by geography 2015-2020 ($ billions)
Exhibit 15: Global postmenopausal osteoporosis drugs market by geography 2015-2020
Exhibit 16: Postmenopausal osteoporosis drugs market in Americas 2015-2020 ($ billions)
Exhibit 17: Postmenopausal osteoporosis drugs market in EMEA 2015-2020 ($ billions)
Exhibit 18: Postmenopausal osteoporosis drugs market in APAC 2015-2020 ($ billions)
Exhibit 19: Global postmenopausal osteoporosis drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 20: Percentage share of women in age group of 60 years and older 2015
Exhibit 21: Percentage share of women in age group of 80 years and above 2015
Exhibit 22: Impact of drivers
Exhibit 23: Impact of drivers and challenges
Exhibit 24: Revenue from sales of major drugs in global postmenopausal osteoporosis drugs market 2013-2015 ($ millions)
Exhibit 25: Eli Lilly: YoY revenue and growth rate of FORTEO 2015 ($ billions)
Exhibit 26: Eli Lilly: Geographical segmentation of FORTEO 2015
Exhibit 27: Eli Lilly: YoY revenue and growth rate of Evista 2015 ($ millions)
Exhibit 28: Eli Lilly: Geographical segmentation of Evista 2015
Exhibit 29: Eli Lilly: Key takeaways
Exhibit 30: Amgen: YoY revenue and growth rate of Prolia 2013-2015 ($ millions)
Exhibit 31: Amgen: Geographical segmentation of Prolia 2015
Exhibit 32: Amgen: Key takeaways
Exhibit 33: Merck: YoY revenue and growth rate of Fosamax 2013-2015 ($ millions)
Exhibit 34: Merck: Key takeaways
Exhibit 35: Novartis: Key takeaways



【掲載企業】

Eli Lilly, Amgen, Merck, Novartis, Allergan, Amgen Astellas Biopharm, Deltanoid Pharmaceuticals, Noven, Novo Nordisk, Osteologix, Pfizer, PhytoHealth, Radius Health, Tarsa Therapeutics, UCB, Uni-Bio Science Group, Upsher-Smith Laboratories, Watson Pharmaceuticals, Zosano Pharma.


【資料のキーワード】

閉経後骨粗鬆症、閉経後骨粗鬆症治療薬、医薬品、パイプライン

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[閉経後骨粗鬆症治療薬の世界市場2016-2020]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆